Valgen Medtech is a technology company.
Valgen Medtech has raised $190.0M across 1 funding round.
Valgen Medtech has raised $190.0M in total across 1 funding round.
Valgen Medtech is a medical technology company specializing in interventional devices for treating structural heart diseases, particularly mitral and tricuspid valve repair.[1][2] It develops products like the DragonFly transcatheter edge-to-edge repair (TEER) system, DragonRing catheter-based mitral annuloplasty device, MitralStitch artificial chordae implantation system, radiation protection screens, balloon dilation catheters, and septal puncture systems, targeting cardiovascular interventions to improve patient outcomes.[1][3] The company serves patients with valvular regurgitation, especially those with atrial fibrillation-related mitral issues, addressing unmet needs in minimally invasive heart treatments amid rising demand for transcatheter solutions.[1][3] Founded in 2015 and headquartered in Hangzhou, Zhejiang, China, Valgen has raised $133M in funding, including a Series B round, with investors like Qiming Venture Partners, Lake Bleu Capital, and HongShan, and operates as a subsidiary of Dinova Medical while backed by DCP Capital.[1][5] Key milestones include over 300 DragonFly implants in China and positive 12-month pivotal trial results in 2023, signaling strong growth momentum toward commercialization.[1]
Valgen Medtech was founded in 2015 in Hangzhou, China, as Hangzhou Valgen Medtech Co., Ltd., focusing on innovative interventional technologies for heart valve diseases.[1][3] While specific founders are not detailed in available sources, the company has been led by figures like Fang Yan in supervisory roles, and it emerged amid China's push for advanced medtech in structural cardiology.[1][4] The idea stemmed from gaps in treating mitral and tricuspid valve lesions, leading to independently developed "Dragon-" series products simulating surgical techniques via catheter delivery.[3] Pivotal early traction included the DragonFly system's successful implants in over 300 patients and the world's first human implantation of DragonRing on October 28, 2022, by Professor Mao Chen's team at West China Hospital, marking a breakthrough in transfemoral annuloplasty for functional mitral regurgitation.[1][3] These moments built Valgen's reputation as a "Tool Box for structural heart diseases," expanding from TEER to annuloplasty and chordae systems.[3]
Valgen stands out in the crowded structural heart medtech space through:
Valgen rides the global surge in transcatheter structural heart interventions, a trend exploding due to aging populations, rising valve disease prevalence, and preferences for less invasive alternatives to open-heart surgery.[1][3] Timing is ideal in China, the world's second-largest medtech market, where domestic innovation accelerates amid regulatory support for homegrown devices post-2023 trial successes.[1] Favorable forces include investor influx into cardio medtech (e.g., Qiming, HongShan) and competitive gaps versus Western leaders like Edwards Lifesciences, allowing Valgen to capture share with cost-effective, tailored solutions.[1][5] It influences the ecosystem by pioneering "toolbox" approaches—combining TEER, annuloplasty, and chordae—potentially standardizing hybrid techniques and exporting Chinese IP globally.[3]
Valgen is poised for explosive growth with DragonFly's China launch and DragonRing's clinical expansion, likely securing NMPA approvals soon and eyeing international markets like the US/EU via trials.[1][3] Trends like AI-guided imaging and combo-device therapies will amplify its toolbox model, while partnerships (e.g., Dinova, DCP Capital) fuel scaling.[1][5] Its influence may evolve from China innovator to global contender, challenging incumbents if trial data sustains and funding supports pivotal studies—watch for Series C and first overseas implants to confirm trajectory.[1] This positions Valgen as a medtech dark horse transforming valve repair accessibility.
Valgen Medtech has raised $190.0M in total across 1 funding round.
Valgen Medtech's investors include Qiming Venture Partners.
Valgen Medtech has raised $190.0M across 1 funding round. Most recently, it raised $190.0M Series B in May 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2021 | $190.0M Series B | Qiming Venture Partners |